WALTHAM, Mass., May 11, 2026 – Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases, today announced that the U.S. Food and...
Program
Molecule
Potential Indications
Discovery
Lead Optimization
Preclinical Development
Phase 1a
Phase 1b/2
Late-Stage Development
SARM1 inhibition
SIR2501
CIPN, ALS & neurodegenerative diseases
NAMPT activation
SIR4156
Neuronal & muscular degenerative diseases & metabolic diseases
RIPK1 inhibition
SIR9900
Inflammation & Immunological diseases, traumatic CNS conditions
Undisclosed
SIR8752
Inflammation & Immunological diseases
Undisclosed
SIR0811
Neurodegenerative diseases
Brain Delivery Module (BDM)
Therapeutic payload / BDM
Neurodegenerative diseases
Early-stage programs
Undisclosed
Program
SARM1 inhibition
Molecule
SIR2501
Potential Indications
CIPN, ALS & neurodegenerative diseases
Phase
Phase 1b/2
Program
NAMPT activation
Molecule
SIR4156
Potential Indications
Neuronal & muscular degenerative diseases & metabolic diseases
Phase
Phase 1b/2
Program
RIPK1 inhibition
Molecule
SIR9900
Potential Indications
Inflammation & Immunological diseases, traumatic CNS conditions
Phase
Phase 1b/2
Program
Undisclosed
Molecule
SIR8752
Potential Indications
Inflammation & Immunological diseases
Phase
Preclinical Development
Program
Undisclosed
Molecule
SIR0811
Potential Indications
Neurodegenerative diseases
Phase
Preclinical Development
Program
Brain Delivery Module (BDM)
Molecule
Therapeutic payload / BDM
Potential Indications
Neurodegenerative diseases
Phase
Preclinical Development
Program
Early-stage programs
Molecule
Potential Indications
Undisclosed
Phase
Discovery
